The nickname that ran ahead of the evidence
Nobody at Lilly ever called it GLP-3. The internet did — a nickname minted for a molecule whose official name, retatrutide, resists neither pronunciation nor recall. The “3” counts receptors: GLP-1, GIP, and glucagon, three axes of the metabolic system activated by one engineered peptide. Strictly, GLP-3 is a mislabel — there is a real GLP-3 peptide fragment of proglucagon with no drug attached, and Lilly itself calls the nickname scientifically inaccurate. But nicknames tell you what a culture expects. This one expected a third generation: better than semaglutide, better than tirzepatide, a step change.
For three years that expectation ran on a phase 2 trial. Now five phase 3 trials have reported, and the bull case is no longer a vibe. This article is that case, stated as strongly as the evidence allows — and paired with the four asterisks it must survive. Both halves are the bull case. A thesis that only lists its own wins is marketing.
Not a prediction that the drug will win, but the strongest honest version of the argument that it will — with its risks priced in, not hidden. Every number below is the published primary analysis unless labeled otherwise. Where the bull case rests on sponsor topline or cross-trial inference, it says so.
Pillar one: the ceiling moved
Every generation of this drug class has a ceiling — the mean weight loss at the top published dose in its pivotal trial, on the analysis that counts everyone randomized. Here is that ladder, each rung a published primary result:
| Drug | Pivotal trial | Top published dose | Clock |
|---|---|---|---|
| Semaglutide | STEP 1 | −14.9% | 68 weeks |
| Tirzepatide | SURMOUNT-1 | −20.9% | 72 weeks |
| CagriSema | REDEFINE-1 | −20.4% | 68 weeks |
| Retatrutide | TRIUMPH-1 | −25.0% | 80 weeks |
The published TRIUMPH-1 numbers behind retatrutide’s rung: 2,339 adults with obesity and no diabetes, 80 weeks, treatment-regimen estimand — mean body weight fell 17.6% (4 mg), 23.7% (9 mg), and 25.0% (12 mg) versus 3.9% on placebo (Jastreboff et al., NEJM, 2026). Against the class’s published ceilings — semaglutide’s 14.9% in STEP 1 (Wilding et al., NEJM, 2021), tirzepatide’s 20.9% in SURMOUNT-1 (Jastreboff et al., NEJM, 2022) — that is roughly four points clear of the best-published injector, and 45.3% of participants at the top dose lost ≥30% of body weight, a level long associated with bariatric surgery.
Two honest caveats ride along. The clock: retatrutide’s 80 weeks is longer than SURMOUNT-1’s 72, so part of the gap is time on drug. And the estimand: 25.0% counts everyone randomized; Lilly’s on-treatment figure for the same arm is 28.3% at 80 weeks and 30.3% at 104 weeks in the BMI-≥35 extension — the number the headlines printed (Lilly, 21 May 2026). If you compare retatrutide’s 25.0% to tirzepatide’s 20.9%, you are comparing treatment-regimen to treatment-policy estimands across different populations and durations — directionally fine for a bull case, exact as a measurement it is not.
The bull thesis lives on 25.0% (published, counts everyone) while the marketing lives on 28.3% (on-treatment). Both are real analyses of the same trial. The honest bull quote is 25.0% and lets the reader know the other number exists — which is exactly what the nickname-owning gray-market pages will not do.
Pillar two: it beat a competitor head-to-head
Cross-trial comparisons are the weakest form of evidence in this class. Head-to-head trials are the strongest. Retatrutide now has one, and it won. In TRANSCEND-T2D-2, the first phase 3 trial to compare retatrutide with another incretin, 1,298 adults with type 2 diabetes on metformin were randomized to retatrutide 9 mg, 12 mg, or Ozempic (semaglutide) 2 mg — the highest approved diabetes dose — for 80 weeks. At 12 mg, retatrutide lowered A1C by 2.2 percentage points versus 1.8 for semaglutide, and produced 20.9% mean weight loss versus 9.4% — more than double (Lilly, 28 October 2026; superiority of the 12 mg dose on A1C was controlled for type 1 error).
That is a real win, and it converts the bull case from “biggest placebo-controlled numbers” to “beat the incumbent injectable in the trial type that matters.” But read the population line: adults with type 2 diabetes, mean A1C 8.3%, baseline weight 225.8 lb — not the obesity-without-diabetes population of TRIUMPH-1, and not a comparison against Zepbound (tirzepatide) at its obesity dose. The bull case against semaglutide is measured. The bull case against tirzepatide remains an inference — no head-to-head exists.
SURMOUNT-5 already showed tirzepatide beating semaglutide 20.2% to 13.7% at 72 weeks (Aronne et al., NEJM, 2025). Retatrutide has no equivalent trial against tirzepatide. Until one reads out, “better than Zepbound” is the comparison the designs cannot support — the same discipline the site applies to every other cross-trial league table.
Pillar three: it is not just a weight drug
A weight drug becomes a metabolic franchise when the same molecule moves endpoints beyond the scale. Retatrutide’s program has now reported signals across knee osteoarthritis pain, sleep apnea, kidney markers, liver-fat reduction, and cardiovascular risk factors — the breadth that turned semaglutide from a diabetes drug into a cultural event after SELECT (Lincoff et al., NEJM, 2023). TRIUMPH-1’s knee-osteoarthritis subgroup saw pain scores fall further than placebo; TRIUMPH-4 confirmed it in a dedicated trial; the sleep-apnea subgroup in TRIUMPH-1 saw apnea–hypopnea events fall by 34.3 per hour at 9 mg against 9.9 on placebo (Jastreboff et al., NEJM, 2026).
The newest organ to report is the kidney. In TRANSCEND-CKD, a 24-week mechanistic trial in adults with obesity and chronic kidney disease, retatrutide cut urinary albumin-to-creatinine ratio by a median 49.2% versus placebo, with lower intraglomerular pressure and kidney fat and no change in measured GFR (Heerspink et al., ASN Kidney Week 2026) — an albuminuria signal in the same family as the one that made semaglutide’s kidney-outcome story, at roughly twice the magnitude reported for FLOW, though from a far smaller and shorter mechanistic trial. Bull case: the third receptor may be earning its seat beyond the scale.
And the risk-factor table from TRIUMPH-3 — triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, hsCRP halved at the top dose (Lilly, 23 July 2026) — is the profile of a molecule being positioned for people whose obesity arrives with cardiovascular disease already attached.
Asterisk three: the heart question is open
The franchise-making result for this class was SELECT: semaglutide reduced major adverse cardiovascular events by 20% (hazard ratio 0.80, 95% CI 0.72–0.90) in 17,604 people with established cardiovascular disease (Lincoff et al., NEJM, 2023). Retatrutide’s TRIUMPH-3 was that trial’s population — severe obesity, established CVD — but not that trial’s size or clock: 1,949 participants, 80 weeks, weight as the primary endpoint, cardiovascular events as an exploratory comparison. The result: 44 vs 52 MACE-5 events (HR 0.82, 95% CI 0.55–1.22) and 27 vs 23 MACE-3 events (HR 1.12, 95% CI 0.64–1.96). Both intervals cross 1.
The bull case reads that as “reassuringly neutral, underpowered by design.” The bear case reads MACE-3 point estimate above 1 and notes that glucagon — the third receptor — raises heart rate. Neither reading is available yet as a fact. A dedicated cardiovascular-outcomes trial exists in the program; until it reports, the heart question is open, and the honest bull case says so rather than borrowing semaglutide’s SELECT halo.
SELECT proved cardiometabolic drugs can reduce events, not that incretins as a class inherit the benefit. TRIUMPH-3’s intervals cross 1; a neutral-ish point estimate on MACE-5 and a slightly unfavorable MACE-3 point estimate are consistent with anything from a modest benefit to no difference to modest harm. Open, not answered.
Asterisk four: the name is the risk
Everything above describes an investigational molecule with five positive phase 3 trials and a planned Q1 2027 U.S. filing. Not an approved drug. But the nickname “GLP-3” already circulates in the gray market, where vials labeled retatrutide sell ahead of any approval — the same pattern that made “Ozempic” a synonym for semaglutide long before the gray market caught up. The buyer who searches “GLP-3” is often reaching for the expectation, not the molecule.
The risk is asymmetric. If the filing slips or a safety signal emerges, the nickname keeps selling while the science pauses — a gray-market version of the two-numbers problem. The bull case’s last pillar is therefore not a trial result but a stance: name the molecule, cite the trial, and let the published number — not the nickname — carry the weight.
The science is strong: published, replicated, five-for-five in phase 3. The page — gray-market vials, nickname-driven search, an unapproved molecule sold as a generation — is where the risk lives. Bullish on the science, sceptical on the page. That is the whole case in one line.
The verdict, with prices attached
Stated as strongly as the evidence allows: retatrutide is the most efficacious weight-loss drug candidate yet tested in pivotal trials, with a published 25.0% mean weight loss at the top dose over 80 weeks, a head-to-head win over the highest approved dose of semaglutide in type 2 diabetes, breadth beyond weight, and a regulator-ready data package with a planned Q1 2027 filing. Every pillar is cited; every asterisk is priced.
What would falsify it: a head-to-head against tirzepatide that fails to separate; a cardiovascular-outcomes trial that lands on the wrong side of 1; a filing slip past Q1 2027 into a competitive window where oral orforglipron — approved as Foundayo in April 2026 (Lilly, 1 April 2026) — and CagriSema close the efficacy gap from cheaper or more convenient positions. The bull case does not claim the molecule will win. It claims the evidence now exists to take the claim seriously — and the four asterisks are the price of holding it honestly.
The deeper story is the one the triple-agonist explainer tells: the class did not get louder, it learned to play chords. The bull case for GLP-3 is really a bet that the chord — GLP-1, GIP, and glucagon in one molecule, at a balanced ratio — is a better instrument than the two-note version. Phase 3 moved the ceiling. The verdict on the chord itself — what the third receptor actually contributes — waits on comparisons the published trials have not yet run.
Common questions
- What is the GLP-3 bull case?
- That retatrutide — the molecule the internet nicknamed “GLP-3” — is the most efficacious weight-loss drug candidate yet tested, backed by five positive phase 3 trials, with a head-to-head win over Ozempic’s highest approved diabetes dose and breadth beyond weight (knee pain, sleep apnea, kidney markers). The honest version also names what it must survive: the two-numbers problem, no head-to-head against tirzepatide, an unresolved cardiovascular question, and an unapproved molecule wearing a nickname.
- Is GLP-3 a real hormone or drug class?
- No. GLP-3 is a nickname, not a hormone or an FDA class. There is a genuine GLP-3 peptide fragment of proglucagon, but the drug nickname refers to retatrutide, Lilly’s investigational triple agonist of GLP-1, GIP, and glucagon receptors — “three receptors,” hence “3.” Lilly itself calls the label scientifically inaccurate. The bull case is about the molecule, not the name.
- How much weight did retatrutide cause in phase 3?
- In the published TRIUMPH-1 trial, mean weight fell 17.6% (4 mg), 23.7% (9 mg), and 25.0% (12 mg) at 80 weeks versus 3.9% on placebo — the treatment-regimen analysis counting everyone randomized. Lilly’s on-treatment figure for the same 12 mg arm is 28.3% at 80 weeks and 30.3% at 104 weeks in a higher-BMI extension. Two analyses of one trial, not two results.
- Is retatrutide better than tirzepatide or semaglutide?
- Against semaglutide there is now a head-to-head: in TRANSCEND-T2D-2, retatrutide lowered A1C 2.2 vs 1.8 points and produced 19.5–20.9% weight loss vs 9.4% for Ozempic 2 mg over 80 weeks, in type 2 diabetes. Against tirzepatide there is no head-to-head trial; cross-trial league tables compare different populations and durations, so any “better than Zepbound” claim is an inference, not a measurement.
- When will retatrutide be approved?
- It is not approved. Lilly has said it plans a U.S. biologics license application in the first quarter of 2027. A filing plan is not an approval; with a standard review the decision would land in late 2027 at the earliest. Meanwhile an unapproved molecule already sells in the gray market — the risk the nickname carries.
- What are retatrutide's main risks?
- Gastrointestinal effects are the most common adverse events, mostly during dose escalation; dysesthesia (sensory disturbance) appears more often than placebo and on semaglutide in the head-to-head; and in TRIUMPH-3 the cardiovascular event comparison did not show a benefit — the MACE-3 hazard ratio was 1.12 (95% CI 0.64–1.96), which crosses 1. Discontinuation for adverse events ran up to 13.5% at 12 mg vs 4.8% placebo in TRIUMPH-3.
Keep going
- Two numbers, one trial — why the headline and the label disagree
- Retatrutide — the triple agonist monograph
- What is retatrutide? The mechanism explainer
- Why tirzepatide isn’t two drugs in one — the dual agonist it must beat
- The hormone we tried to block — glucagon's century
- Early adopters — the gray market ahead of the evidence
- The incretins & metabolic family
- Ask the research agent about the ceiling race
Educational reference on mechanism and the state of the evidence, summarized from public scientific literature and clinical-trial disclosures and simplified in places. Not individualized medical advice or a prescription. Where a dose or regimen appears it is reported from its source as research literacy — so you can read the evidence yourself — not an instruction to dose. Compounds are named to explain the science. Investigational, not approved: retatrutide. Status checked November 2026.